

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

SPECIAL FEATURES

CCR Translations

- 3649** **A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers**
Noelia Silva-Pilipich and Cristian Smerdou
See related article, p. 3715
- 3652** **Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab**
Fang-Chi Hsu and Yun Yen
See related article, p. 3735
- 3655** **Novel Therapies in Cancer: Trials and Tribulations**
Saiama N. Waqar and Ramaswamy Govindan
See related article, p. 3937

CCR Perspectives in Regulatory Science and Policy

- 3658** **Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding**
Jorge E. Cortes, Elisabetta Abruzzese, Elyce H. Cardonick, Sonia Hernández-Díaz, Jamie Gutierrez, Mary S. Sardegna, Erica Torres-Chavez, Miriam Dinatale, Catherine C. Lerro, Brenda J. Gehrke, Stacy S. Shord, R. Angelo De Claro, Marc R. Theoret, Peter J. DeMaria, and Kelly J. Norsworthy

Reviews

- 3667** **PI3K Inhibitors in Hematology: When One Door Closes...**
Sigrid S. Skånland, Klaus Okkenhaug, and Matthew S. Davids
- 3676** **TGF β in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance**
Allan M. Johansen, Steven D. Forsythe, Callum T. McGrath, Grayson Barker, Hugo Jimenez, Ravi K. Paluri, and Boris C. Pasche
- 3688** **Facts and Hopes in the Systemic Therapy of Biliary Tract Carcinomas**
Angela Lamarca and Teresa Macarulla

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORTS

- 3697** **A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer**
Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller, Juliana Eng, Bob Li, Isabel Preeshagul, Fernando C. Santini, Michael Offin, Kenneth Ng, Paul Paik, Christina Larsen, Michelle S. Ginsberg, Yvonne Lau, Xinyuan Zhang, Marina K. Baine, Natasha Rekhman, and Charles M. Rudin

CLINICAL TRIALS: TARGETED THERAPY

- 3704** **Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group**
Beatriz Rey-Búa, Carlos Grande, José J. Sánchez Blanco, Pau Abrisqueta, Antonio Gutiérrez, Ángel Ramírez Páyer, Eva Giné, Izaskun Zeberio Etxetxia, Maria J. Terol, Fátima de la Cruz Vicente, Rafel Andreu, Maria J. Ramirez, Adolfo de la Fuente, Maria C. Viguria, María J. Peñarrubia, Ana Jiménez-Ubieto, Santiago Montes-Moreno, Armando López-Guillermo, María D. Caballero, and Alejandro Martín García-Sancho

CLINICAL TRIALS: IMMUNOTHERAPY

- 3715** **Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial**
Santeri A. Pakola, Katriina J. Peltola, James H.A. Clubb, Elise Jirovec, Lyna Haybout, Tatiana V. Kudling, Tuomo Alanko, Riitta Korpisaari, Susanna Juteau, Marjut Jaakkola, Jorma Sormunen, Jukka Kempainen, Annabrita Hemmes, Teijo Pellinen, Mirte van der Heijden, Dafne C.A. Quixabeira, Claudia Kistler, Suvi Sorsa, Riikka Havunen, Joao M. Santos, Victor Cervera-Carrascon, and Akseli Hemminki
See related commentary, p. 3649

TABLE OF CONTENTS

3726 Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma

Martin Forster, Irene Brana, Antonio L. Pousa, Bernard Doger, Patricia Roxburgh, Pawan Bajaj, Julio Peguero, Matthew Krebs, Enric Carcereny, Grisma Patel, Christian Mueller, Chrystelle Brignone, and Frederic Triebel

3735 Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

Birgit S. Geurts, Laurien J. Zeverijn, Lindsay V.M. Leek, Jade M. van Berge Henegouwen, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Joris van de Haar, Annemiek van Ommen-Nijhof, Marleen Kok, Paul Roepman, Anne M.L. Jansen, Wendy W.J. de Leng, Maja J.A. de Jonge, Ann Hoeben, Carla M.L. van Herpen, Hans M. Westgeest, Lodewyk F.A. Wessels, Henk M.W. Verheul, Hans Gelderblom, and Emile E. Voest

See related commentary, p. 3652

3747 A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma

Dongjian Chen, Yu Zhu, Zhi Chen, Songfu Jiang, Haiyan He, Wanting Qiang, Fang Xiang, Xuedong Sun, and Juan Du

3757 Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers

Jena D. French, Bryan R. Haugen, Francis P. Worden, Daniel W. Bowles, Andrew G. Gianoukakis, Bhavana Konda, Ramona Dadu, Eric J. Sherman, Shaylene McCue, Nathan R. Foster, Yuri E. Nikiforov, Ticiania D.J. Farias, Paul J. Norman, and Lori J. Wirth

3768 A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer

Robert W. Lentz, Tyler J. Friedrich, Patrick J. Blatchford, Kimberly R. Jordan, Todd M. Pitts, Hannah R. Robinson, S. Lindsey Davis, Sunnie S. Kim, Alexis D. Leal, Mathew R. Lee, Meredith R.N. Waring, Anne C. Martin, Adrian T.A. Dominguez, Stacey M. Bagby, Sarah J. Hartman, S. Gail Eckhardt, Wells A. Messersmith, and Christopher H. Lieu

RESEARCH BRIEFS: PRECISION MEDICINE AND THERAPEUTICS

3779 Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition

Leonard Schmiester, Fara Brasó-Maristany, Blanca González-Farré, Tomás Pascual, Joaquín Gavilá, Xavier Tekpli, Jürgen Geisler, Vessela N. Kristensen, Arnaldo Frigessi, Aleix Prat, and Alvaro Köhn-Luque

PRECISION MEDICINE AND IMAGING

3788 Circulating Tumor DNA Dynamics Reveal *KRAS G12C* Mutation Heterogeneity and Response to Treatment with the *KRAS G12C* Inhibitor Divarasib in Solid Tumors

Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi, and the GO42144 study group

3798 Detecting Small Cell Transformation in Patients with Advanced *EGFR* Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

Talal El Zarif, Catherine B. Meador, Xintao Qiu, Ji-Heui Seo, Matthew P. Davidsohn, Hunter Savignano, Gitanjali Lakshminarayanan, Heather M. McClure, John Canniff, Brad Fortunato, Rong Li, Mandeep K. Banwait, Karl Semaan, Marc Eid, Henry Long, Yin P. Hung, Navin R. Mahadevan, David A. Barbie, Matthew G. Oser, Zofia Piotrowska, Toni K. Choueiri, Sylvan C. Baca, Aaron N. Hata, Matthew L. Freedman, and Jacob E. Berchuck

3812 Tumor-Agnostic Genomic and Clinical Analysis of *BRAF* Fusions Identifies Actionable Targets

Monica F. Chen, Soo-Ryum Yang, Jessica J. Tao, Antoine Desilets, Eli L. Diamond, Clare Wilhelm, Ezra Rosen, Yixiao Gong, Kerry Mullaney, Jean Torrisi, Robert J. Young, Romel Somwar, Helena A. Yu, Mark G. Kris, Gregory J. Riely, Maria E. Arcila, Marc Ladanyi, Mark T.A. Donoghue, Neal Rosen, Rona Yaeger, Alexander Drilon, Yonina R. Murciano-Goroff, and Michael Offin

TABLE OF CONTENTS

- 3824 Streamlined Intraoperative Brain Tumor Classification and Molecular Subtyping in Stereotactic Biopsies Using Stimulated Raman Histology and Deep Learning**
David Reinecke, Daniel Ruess, Anna-Katharina Meissner, Gina Fürtjes, Niklas von Spreckelsen, Adrian Ion-Margineanu, Florian Khalid, Tobias Blau, Thomas Stehle, Abdulkader Al-Shugri, Reinhard Büttner, Roland Goldbrunner, Maximilian I. Ruge, and Volker Neuschmelting
- 3837 Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study**
Thijs van der Vaart, Maarten M.J. Wijnenga, Karin van Garderen, Hendrikus J. Dubbink, Pim J. French, Marion Smits, Clemens M.F. Dirven, Johan M. Kros, Arnaud J.P.E. Vincent, and Martin J. van den Bent
- 3845 Playing Russian Roulette: Parent and Adolescent Perspectives on Tumor Surveillance for Adolescents with Cancer Predisposition Syndromes**
Rachel Elias, Alise Blake, Lori Dean, Jessica S. Flynn, Leila Sachner, Lynn Harrison, Rose B. McGee, Kim E. Nichols, and Katianna M. Howard Sharp
- 3881 Multiplexed Spatial Profiling of Hodgkin Reed-Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma**
Maryam Pourmaleki, Caitlin J. Jones, Sabrina D. Mellinghoff, Brian D. Greenstein, Priyadarshini Kumar, Miguel Foronda, Daniel A. Navarrete, Carl Campos, Mikhail Roshal, Nikolaus Schultz, Sohrab P. Shah, Andrea Schietinger, Nicholas D. Socci, Travis J. Hollmann, Ahmet Dogan, and Ingo K. Mellinghoff
- 3894 Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer**
Andrew T. Lenis, Vignesh Ravichandran, Samantha Brown, Syed M. Alam, Andrew Katims, Hong Truong, Peter A. Reisz, Samantha Vasselmann, Barbara Nweji, Karen A. Autio, Michael J. Morris, Susan F. Slovin, Dana Rathkopf, Daniel Danila, Sungmin Woo, Hebert A. Vargas, Vincent P. Laudone, Behfar Ehdaie, Victor Reuter, Maria Arcila, Michael F. Berger, Agnes Viale, Howard I. Scher, Nikolaus Schultz, Anuradha Gopalan, Mark T.A. Donoghue, Irina Ostrovnaya, Konrad H. Stopsack, David B. Solit, and Wassim Abida
- 3904 Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine Leiomyosarcoma**
Horace H.Y. Lee, Kin Long Chow, Ho Shing Wong, Tsz Yan Chong, Alice S.T. Wong, Grace H.W. Cheng, Jasmine M.K. Ko, Hoi Cheong Siu, Maximus C.F. Yeung, Michael S.Y. Huen, Ka Yu Tse, Mark R. Bray, Tak Wah Mak, Suet Yi Leung, and Philip P.C. Ip
- 3919 Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing**
Jian Cui, Xiaoyun Li, Shuhui Deng, Chenxing Du, Huishou Fan, Wenqiang Yan, Jingyu Xu, Xiaoqing Li, Tengpeng Yu, Shuaishuai Zhang, Rui Lv, Weiwei Sui, Mu Hao, Xin Du, Yan Xu, Shuhua Yi, Dehui Zou, Tao Cheng, Lugui Qiu, Xin Gao, and Gang An
- 3937 Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol**
Jade M. van Berge Henegouwen, Laurien J. Zeverijn, Birgit S. Geurts, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Alwin D.R. Huitema, Filip Y.F. de Vos, Katrien Grünberg, Haiko J. Bloemendal, Henk M.W. Verheul, Emile E. Voest, and Hans Gelderblom
See related commentary, p. 3655
- TRANSLATIONAL CANCER MECHANISMS AND THERAPY**
- 3855 Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids**
Kanve N. Suvilesh, Yariswamy Manjunath, Yulia I. Nussbaum, Mohamed Gadelkarim, Murugesan Raju, Akhil Srivastava, Guangfu Li, Wesley C. Warren, Chi-Ren Shyu, Feng Gao, Matthew A. Ciorba, Jonathan B. Mitchem, Satyanarayana Rachagani, and Jussuf T. Kaifi
- 3868 An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials**
Paul Jank, Thomas Karn, Marion van Mackelenbergh, Judith Lindner, Denise Treue, Jens Huober, Knut Engels, Christine Solbach, Kurt Diebold, Frederik Marmé, Volkmar Müller, Andreas Schneeweiss, Hans-Peter Sinn, Tanja Fehm, Christian Schem, Elmar Stickeler, Peter Fasching, Jan Budczies, Bärbel Felder, Valentina Nekljudova, Johannes Holtschmidt, Michael Untch, Carsten Denkert, and Sibylle Loibl

TABLE OF CONTENTS

- 3944** **Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma**
Ester Lozano, Mari-Pau Mena, Glòria Garrabou, Oriol Cardús, Tania Díaz, David F. Moreno, Joan Mañé-Pujol, Aina Oliver-Caldés, Anthony Battram, Natalia Tovar, María-Teresa Cibeira, Luis-Gerardo Rodríguez-Lobato, Joan Bladé, Carlos Fernández de Larrea, and Laura Rosiñol

- 3957** **Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors**
Giuseppe Curigliano, Hans Curigliano, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, and Aung Naing


CORRECTIONS

- 3956** **Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma**
Keiji Kurata, Mehmet K. Samur, Priscilla Liow, Kenneth Wen, Leona Yamamoto, Jiye Liu, Eugenio Morelli, Annamaria Gulla, Yu-Tzu Tai, Jun Qi, Teru Hideshima, and Kenneth C. Anderson

ABOUT THE COVER

The cover shows a multiplexed immunofluorescence image of a lymph node biopsy from a patient with syncytial classic Hodgkin lymphoma. The malignant Hodgkin Reed-Sternberg cells (*red*) are surrounded by B cells (*yellow*), T cells (*magenta*), and B7-H3 (*white*) positive myeloid cells (*cyan*). For details, see the article by Pourmaleki and colleagues on page 3881 of this issue.

doi: 10.1158/1078-0432.CCR-30-17-CVR



NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR's established policies for authors, please go to <https://aacrjournals.org/pages/editorial-policies#coi>.